Phase II trial of intravenous melphalan in advanced XXXX .

@entity1 @entity137 @entity882 @entity5 @entity3601 @entity14 @entity3028 @entity204
BACKGROUND: Relatively few studies have examined the activity of alkylating agents in the treatment of advanced @entity14 . Recent reports have suggested possible therapeutic activity for high-dose intravenous melphalan administered with autologous bone marrow transplantation (BMT) support. We conducted a phase II study to determine the efficacy of administering intravenous melphalan at doses that do not require BMT support in @entity1 with advanced @entity14 . @entity1 AND METHODS: Fifteen @entity1 with histologically proven, bidimensionally measurable disease were treated. The starting dose of @entity3601 was 30 mg/m2, with dose escalation permitted. RESULTS: No objective responses were observed. @entity137 effects were primarily reversible @entity3028 and @entity882 . There were no treatment-associated @entity204 . CONCLUSION: Melphalan's lack of efficacy at the doses administered does not disprove the steep chemotherapy dose-response relationship postulated for many solid @entity5 . However, we feel that it is unlikely that repetitive courses of high dose melphalan with autologous BMT support will be a practical approach to the management of advanced @entity14 .
